Cellular and T cell engager Immunotherapy
Prophylactic Tocilizumab to Mitigate Cytokine Release Syndrome in Patients Receiving Talquetamab for Relapsed/Refractory Multiple Myeloma: Results From the Phase 1/2 MonumenTAL-1 Study
Gareth Morgan, MD, PHD, FRCP, FRCPATH (he/him/his)
Professor of Medicine, Director of Myeloma Research
NYU Langone Health Perlmutter Cancer Center, United States